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Abstract 
Background: Acute respiratory failure (ARF) is the most frequent complication in patients with hematological 
malignancies and is associated with high morbidity and mortality. ARF etiologies are numerous, and despite extensive 
diagnostic workflow, some patients remain with undetermined ARF etiology.
Methods: This is a post‑hoc study of a prospective multicenter cohort performed on 1011 critically ill hematologi‑
cal patients. Relationship between ARF etiology and hospital mortality was assessed using a multivariable regression 
model adjusting for confounders.
Results: This study included 604 patients with ARF. All patients underwent noninvasive diagnostic tests, and a bron‑
choscopy and bronchoalveolar lavage (BAL) was performed in 155 (25.6%). Definite diagnoses were classified into 
four exclusive etiological categories: pneumonia (44.4%), non‑infectious diagnoses (32.6%), opportunistic infection 
(10.1%) and undetermined (12.9%), with corresponding hospital mortality rates of 40, 35, 55 and 59%, respectively. 
Overall hospital mortality was 42%. By multivariable analysis, factors associated with hospital mortality were invasive 
pulmonary aspergillosis (OR 7.57 (95% CI 3.06–21.62); p < 0.005), use of invasive mechanical ventilation (OR 1.65 (95% 
CI 1.07–2.55); p = 0.02), a SOFA score >7 (OR 3.32 (95% CI 2.15–5.15); p < 0.005) and an undetermined ARF etiology 
(OR 2.92 (95% CI 1.71–5.07); p < 0.005).
Conclusions: In patients with hematological malignancies and ARF, up to 13% remain with undetermined ARF 
etiology despite comprehensive diagnostic workup. Undetermined ARF etiology is independently associated with 
hospital mortality. Studies to guide second‑line diagnostic strategies are warranted.
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Background
Prevalence of cancer increases steadily over time [1] 
and is a leading cause of death worldwide, especially in 
developed countries [2]. This increasing prevalence may 
be explained by improved sensitivity of diagnostic tests, 
enhanced efficacy and reduced toxicities of chemother-
apy regimens [3], recently released targeted therapies 
and new drugs contributing to increase overall survival 
[4], as well as recent advances in stem cell transplanta-
tions [5].
Acute respiratory failure (ARF) is the most frequent com-
plication in hematological malignancy (HM) patients, with 
an incidence reaching 50% [6, 7], leading to high rate of ICU 
admission [8–11]. Although prognosis of critically ill HM 
patients improved over the last years [12–17], ARF remains 
associated with high mortality [8]. Strikingly, mortality rate 
in that setting is related to ARF etiology [18–20], suggesting 
that the diagnostic strategy could impact on outcomes.
ARF etiologies are numerous [6, 20–25] mainly related 
to bacterial or opportunistic infections, underlying 
disease-specific infiltration [26], or drug-related pul-
monary toxicity [27]. Age and associated comorbidities 
also account for less specific ARF causes such as COPD 
exacerbation or cardiac pulmonary edema (CPE) [28]. 
Therefore, diagnosis of ARF could be difficult to identify. 
Then, a careful, accurate and efficient diagnostic strat-
egy should be implemented to increase diagnostic rate 
[29, 30]. For instance, a clinical approach easily feasible 
at the bedside can both assess the most likely diagnosis 
and guide the best diagnostic approach using noninvasive 
diagnostic tests or fiberoptic bronchoscopy with bron-
choalveolar lavage (BAL) (the DIRECT approach [6, 31]). 
In that strategy, invasive diagnostic tests, including BAL, 
would be performed only for specific situations [32–34].
ARF etiology remains undetermined despite a com-
prehensive diagnostic workup in up to 25% of the cases 
[33, 35]. Moreover, several studies have reported that 
immunocompromised patients with undetermined ARF 
etiology have an increased mortality [18, 32, 36]. How-
ever, this finding has never been properly assessed in a 
large study. Higher mortality for patients with undeter-
mined diagnosis could lead to reinforce our willingness 
to improve overall diagnostic strategy or to develop new 
diagnostic tools before discussing lung biopsy.
We sought to appraise the relation between an unde-
termined ARF etiology and mortality in a large cohort of 
critically ill hematology patients. The second objective of 
this study was to assess the yield of invasive procedures, 
such as BAL, in recent years.
Patients and methods
 This research is a post hoc analysis of a prospective 
cohort including 1011 hematological patients admitted to 
ICU (a study led by the Groupe de Recherche en Réani-
mation Respiratoire en Onco-Hématologie (GRRR-OH)). 
As previously published [8], fifteen French and two Bel-
gian ICUs, all familiar with the management of critically 
ill HM patients, included patients in this cohort within a 
16-month period (January 2010–May 2011). The study 
was approved by the appropriate ethics committees in 
France (CEERB Bichat, 0235) and Belgium (a different 
IRB for Brussels and Ghent) and declared on clinical trial 
(ClinicalTrials.Gov: NCT01172132). All patients or rela-
tives were informed and consented to participate in the 
study.
Briefly, in the prospective cohort, all patients admit-
ted to ICU with HM were included in the study regard-
less of the reason of admission. HM was considered if 
initial diagnosis was performed or relapse occurs within 
5 years before ICU admission. Patients’ characteristics at 
admission and during ICU stay were prospectively col-
lected in a dedicated electronic form. For this post hoc 
study, only patients with acute respiratory failure (ARF) 
at ICU admission were analyzed. ARF was defined by an 
oxygen saturation <90% or PaO2 <60 mmHg on room air, 
tachypnea (respiratory rate >30/min) or labored breath-
ing, starting within the last 72 h before ICU admission. 
ARF patients were included regardless of their need for 
high flow oxygen, noninvasive or invasive mechanical 
ventilation (IMV).
Patients underwent a global comprehensive assess-
ment to identify ARF etiologies. Invasive or noninvasive 
diagnostic strategy was performed according to clinical 
evaluation and CT findings, as previously described [33]. 
Noninvasive diagnostic tests were blood culture, PCRs 
for HSV and CMV, serum aspergillus galactomannan, 
sputa examination, urine antigen tests for Streptococcus 
pneumoniae and Legionella pneumophila, nasopharyn-
geal aspirate or swab including atypical bacteria tests, 
blood cultures and echocardiography (see Additional 
file  1). Diagnostic tests were analyzed if they were per-
formed between 2  days before and 4  days after ICU 
admission. Considering that all participating centers were 
used to manage such immunocompromised critically ill 
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HM patients and participated in previous studies con-
cerning the diagnostic management of these patients [32, 
33], diagnostic strategy performed was the one of the 
previous studies [33].
Four diagnostic categories were a priori defined by 
the investigators, based on the need of specific patient’s 
management (i.e., antibiotics, chemotherapy and ster-
oids, or antifungal, antipneumocystis or antiviral agents) 
and on previous studies from this group [33]. For each 
patient, three investigators (EA, VL and FV) analyzed 
the charts blinded from the diagnosis established by cli-
nicians in charge. Cases of disagreement were then dis-
cussed among the three investigators until a consensus 
could be reached. For 17 patients, no consensus could be 
reached, the complete charts were analyzed and the diag-
nosis retained by 2 of the 3 investigators was kept. For 5 
patients, the three investigators concluded on a differ-
ent diagnosis, and no consensus could be reached. These 
patients were left with an undetermined diagnosis.
Among the four diagnostic categories, the first group 
included patients with pneumonia as defined by a clini-
cally or microbiologically documented low respiratory 
tract infection. Clinically documented infection referred 
to patients with all clinical and radiological criteria for 
bacterial pneumonia without any microbiological posi-
tive results [33]. Microbiologically documented infec-
tions were pneumonia with a positive bacterial or viral 
result from blood cultures (including HSV pneumonia), 
sputa, nasopharyngeal aspirates, tracheal aspirates or 
BAL. The second group included patients with non-
infectious diagnoses, mostly corresponding to cases of 
ARF from pulmonary infiltration by the malignancy 
[26], CPE and drug-related pulmonary toxicity [27]. The 
third group included patients with ARF from opportun-
istic infections corresponding to invasive pulmonary 
aspergillosis according to EORTC criteria [37], proven 
pneumocystis pneumonia (positive direct examination 
or immunofluorescence on induced sputa or BAL) and 
other invasive fungal infections, CMV infections and 
parasitic infections [33]. Last, patient had undetermined 
diagnosis when no diagnosis could be made despite non-
invasive diagnostic tests, bronchoscopy and BAL when 
performed and a global patient’s assessment by the ICU 
team and the hematologist consultant (see Additional 
file 1).
Results were expressed as median and 25th and 75th 
quartiles [Q1–Q3] for continuous data and numbers and 
percentages for categorical data. Marginal association 
between single variables and outcome was assessed by 
Wilcoxon rank-sum tests for quantitative variables and 
Fisher’s exact test or Chi-square test with Yates’ conti-
nuity correction for categorical variables when Fisher’s 
exact test was computationally impossible.
Factors associated with mortality were assessed using 
multivariate logistic model. Variables associated with 
the outcome in the first study [8] (poor performance sta-
tus, Charlson comorbidity index, recipient of allogeneic 
hematopoietic stem cell transplantation (AHSCT), com-
plete or partial remission, time for hospital to ICU admis-
sion <24  h, SOFA score, admission for cardiac arrest, 
admission for acute respiratory failure, organ infiltra-
tion by the malignancy and invasive pulmonary aspergil-
losis) were included in the model. Invasive mechanical 
ventilation and undetermined diagnosis were included 
in the model for this study. A selection procedure was 
performed using a backward algorithm with a stopping 
criteria defined by p values below 0.05 for all variables 
included in the model. Odds ratios of variables present in 
the final model are given with their 95% confidence inter-
vals. Goodness-of-fit test of the final model was checked 
using the le Cessie–van Houwelingen test statistic [38].
Survival curves were obtained using the Kaplan–Meier 
estimator. Differences between survivals were tested 
using log-rank test. All tests were two sided at the 0.05 
significance level. Analyses were performed using R sta-
tistical package (http://www.R-project.org).
Results
Seven hundred and one HM patients with respiratory 
symptoms were reviewed, including 604 with acute 
respiratory failure who were included in final analysis 
(Fig.  1). Our study population included mainly males 
(n  =  368, 61%) with a median age of 60 [50–70]. The 
most prevalent HM patients were acute myeloid leuke-
mia (AML, n = 168, 28%) and non-Hodgkin lymphoma 
(NHL, n  =  164, 27%). Complete or partial remission 
Fig. 1 Patients flow diagram. Patients with respiratory symptoms 
were excluded if they didn’t reach any pre‑defined ARF criterion. ICU 
Intensive care unit, ARF Acute respiratory failure
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concerned 138 (24%) patients, and 107 (17.7%) patients 
were AHSCT recipients. Most of patients (72%) received 
antibiotics before ICU admission and/or prophylaxis 
(15.6%). Altered performance status concerned 124 
(20.4%) patients, 182 (30%) patients were neutropenic 
and 270 (47%) patients had at least 3 organ dysfunc-
tions according to SOFA definition [39]. At ICU admis-
sion, the median respiratory rate was 32 [26–38]/min, 
oxygen flow was 7 [3–15]  L/min and two-thirds of the 
patients had 2 or more quadrants involved on chest 
Table 1 Study population according to hospital mortality (N (%)—median [IQR 25–75])
Results were expressed as median and 25th and 75th quartiles [Q1–Q3] for quantitative data and numbers and percentages for categorical data. Marginal association 
between single variables and outcome was assessed by Wilcoxon rank-sum tests for quantitative variables and Fisher’s exact test or Chi-square test with Yates 
continuity correction for categorical variables when Fisher’s exact test was computationally impossible
CR complete remission, NA not available, PR partial remission, IQR inter-quartile range
(N (%)—median [IQR 25–75]) Alive at hospital discharge (n = 349) Patients who died (n = 255, 42%) p value
Age (year) 60 [50–69] 61 [51–71] 0.43
Malignancy
 Acute myeloid leukemia 90 (25.8%) 78 (30.6%) 0.37
 Non‑Hodgkin lymphoma 96 (27.5%) 68 (26.7%)
 Myeloma 49 (14%) 32 (12.5%)
 Chronic lymphocytic leukemia 32 (9.2%) 23 (9%)
 Acute lymphoblastic leukemia 19 (5.4%) 19 (7.4%)
 Myelodysplastic syndrome 18 (5.2%) 12 (4.7%)
 Hodgkin’s disease 14 (4%) 4 (1.6%)
 Others 31 (8.9%) 19 (7.5%)
Disease status at admission
 Earliest phase 120 (34.4%) 88 (34.5%) 0.86
 Progression 137 (39.3%) 103 (40.4%)
 Complete or partial remission 83 (23.8%) 55 (21.6%)
 Unknown 9 (2.5%) 9 (3.5%)
Stem cell transplantation
 Autologous 39 (11.2%) 23 (9.1%) 0.03
 Allogeneic 50 (14.3%) 57 (22.4%)
Poor performance status 55 (15.8%) 69 (27.1%) 0.001
Time from hospital to ICU admission >24 h 159 (46%) 96 (38%) 0.061
Neutropenia 85 (24.4%) 97 (38%) 0.0004
Respiratory rate at admission (/min) 32 [25–37] 35 [25–39] 0.002
Invasive mechanical ventilation at day 1 107 (30.7%) 143 (56.1%) <0.0001
SOFA score >7 108 (32.2%) 162 (66.7%) <0.0001
ARF etiologies
 Infectious etiologies 162 (46.4%) 106 (41.6%) <0.0001
  Clinically documented 60 (17.2%) 21 (8.2%)
  Bacterial infection 56 (16%) 54 (21.2%)
  Viral infection 16 (4.6%) 8 (3.2%)
  Other 30 (8.6%) 23 (9%)
 Non‑infectious lung involvement 127 (36.4%) 69 (27.1%)
  Malignant infiltrate 25 (7.2%) 18 (7.1%)
  Drug‑related lung toxicity 4 (1.1%) 0 (0%)
  Cardiac pulmonary edema 48 (13.8%) 17 (6.7%)
  Other 50 (14.3%) 34 (13.3%)
 Opportunistic infections 28 (8%) 34 (13.3%)
  Invasive pulmonary aspergillosis 6 (1.7%) 24 (9.4%)
  Pneumocystis jirovecii infections 18 (5.1%) 4 (1.6%)
  Other invasive fungal infections 3 (0.9%) 2 (0.7%)
  Other 1 (0.3%) 4 (1.6%)
 Undetermined 32 (9.2%) 46 (18%)
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X-ray. Noninvasive ventilation was started in 205 (33.9%) 
patients among whom 65 required secondary intubation. 
A total of 250 patients (41.4%) needed IMV at day 1. 
Patient’s characteristics are described in Table 1. 
Overall, median number of noninvasive diagnos-
tic test performed in each patient was 4 [2–9], includ-
ing mostly blood cultures (100%), sputum examination 
(85%), induced sputum examination (14%) and serum 
aspergillus galactomannan (75%). For 247 (41%) patients, 
a CT scan was performed. ARF etiologies are reported 
in Table  1. An infectious etiology was diagnosed in 268 
(44.4%) patients, including 110 patients with bacterial 
pneumonia (18.2%), 81 patients with clinically docu-
mented infectious pneumonia (13.4%), 24 patients with 
viral pneumonia (4%) and 53 patients with miscellane-
ous etiologies (8.8%). Non-infectious pulmonary involve-
ment was diagnosed in 196 (32.5%) patients, including 65 
(10.8%) patients with CPE, 43 patients with lung involve-
ment in underlying disease (7.1%) and 88 patients with 
miscellaneous non-infectious etiologies (14.6%), among 
whom 6 patients were diagnosed with intra-alveolar 
hemorrhage, 1 had hypersensitivity pneumonitis and 4 
presented with drug-related pulmonary toxicity. Oppor-
tunistic infections were diagnosed in 62 (10.2%) patients, 
including 30 (5%) patients with invasive pulmonary 
aspergillosis, 22 (3.6%) patients with pneumocystis 
pneumonia and 10 (1.6%) patients with other opportun-
istic diagnoses. For 78 (12.9%) patients, etiology of ARF 
remained undetermined after the complete diagnosis 
strategy.
Table  2 reports the comparison between patients 
with and without undetermined ARF etiology. Patients 
with undetermined ARF etiology were more frequently 
AHSCT recipients (26.9 vs 16.4%, p  =  0.02) and con-
tained a higher proportion of patients with a low per-
formance status (PS > 1, 31 vs 19%, p = 0.01). The delay 
between the diagnosis of the hematological malignancy 
to ARF and the delay between respiratory symptoms 
and ICU admission were not different between the 
2 groups (487  days [53–1552] vs 216  days [18–1220] 
(p = 0.094) and 32 vs 43.7% of patients were admitted to 
ICU within the first 24 hours of respiratory symptoms 
Table 2 Comparison of patients with and without undetermined ARF etiology (N (%)—median [IQR 25–75])
Results were expressed as median and 25th and 75th quartiles [Q1–Q3] for quantitative data and numbers and percentages for categorical data. Marginal association 
between single variables and outcome was assessed by Wilcoxon rank-sum tests for quantitative variables and Fisher’s exact test or Chi-square test with Yates 
continuity correction for categorical variables when Fisher’s exact test was computationally impossible
CR complete remission, NA not available, PR partial remission, IQR inter-quartile range
(N (%)—median [IQR 25–75]) Undetermined diagnosis (n = 78) Others (n = 526) p value
Age (year) 60.5 [52–72] 60 [50–70] 0.53
Malignancy
 Acute myeloid leukemia 20 (25.7%) 148 (28.1%) 0.26
 Non‑Hodgkin lymphoma 21 (26.9%) 143 (27.1%)
 Myeloma 18 (23.1%) 63 (12%)
 Chronic lymphocytic leukemia 8 (10.3%) 47 (9%)
 Acute lymphoblastic leukemia 3 (3.8%) 35 (6.6%)
 Myelodysplastic syndrome 4 (5.1%) 26 (5%)
 Hodgkin’s disease 1 (1.3%) 17 (3.2%)
 Others 3 (3.8%) 47 (9%)
Disease status at admission
 Earliest phase 19 (24.4%) 189 (35.9%) 0.09
 Progression 31 (39.7%) 209 (39.7%)
 Complete or partial remission 23 (29.5%) 115 (21.9%)
 Unknown 5 (6.4%) 13 (2.5%)
Stem cell transplantation
 Autologous 11 (14%) 51 (9.7%) 0.022
 Allogeneic 21 (26.9%) 86 (16.3%)
Performance status 2–4 24 (31%) 100 (19%) 0.025
Delay of admission >24 h 25 (32.1%) 230 (43.7%) 0.072
Neutropenia 26 (33%) 156 (30%) 0.6
Respiratory rate at admission (/min) 35 [28–40] 32 [26–38] 0.13
Invasive mechanical ventilation at day 1 33 (42.3%) 217 (41.3%) 0.88
SOFA score >7 38 (48.7%) 232 (44.1%) 0.39
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onset (p =  0.072), respectively). Also, the proportion of 
patients with neutropenia and the number of patients 
who undergone BAL were not different between the two 
groups (33 vs 29.7%, p = 0.60 and 33.3 vs 25.5%, p = 0.10, 
respectively). Patients with an undetermined diagnosis 
were treated with antibiotics (100%), steroids (65%), anti-
viral therapy (46%) and antifungal therapy (41%).
Overall ICU mortality and hospital mortality were 
30.5 and 42.2%, respectively. Hospital mortality differed 
significantly across diagnostic categories (univariate 
analysis, Fig.  2). Namely, mortality ranged from 35% in 
patients with non-infectious pulmonary involvement to 
59% in patients with undetermined ARF etiology and was 
40 and 55% for patients with infectious and opportunis-
tic etiologies, respectively. Invasive pulmonary aspergil-
losis was associated with the higher-case fatality (80%), 
whereas the lowest mortality was reported in patients 
with pneumocystis pneumonia (18%) (Figs. 2, 3). End-of-
life decision was performed for 152 patients (25%) over-
all, including 26/78 (33.3%) patients in the undetermined 
diagnosis group and 126/536 (23.9%) patients in the other 
groups (p = 0.09).
By multivariable analysis (Fig.  4), factors associated 
with hospital mortality were invasive pulmonary asper-
gillosis (OR 7.49 (95% CI 3.03–21.37); p < 0.005), IMV in 
the first 24 h of ICU admission (OR 1.65 (95% CI 1.06–
2.54); p = 0.02), a SOFA score >7 (OR 3.31 (95% CI 2.15–
5.13); p < 0.005) and an undetermined ARF etiology (OR 
2.71 (95% CI 1.59–4.68); p < 0.005).
As given in Additional file  1: Table  S1, 155 (26%), 
patients underwent bronchoscopy and BAL. As com-
pared with the no-BAL population, these patients were 
significantly younger (58 [49–67.5] vs 61 [52–71] year 
old, p  =  0.019), with a controlled underlying disease 
(CR or PR in 31 vs 20% of the patients, p = 0.026), more 
often AHSCT recipients (24.7 vs 15.4%, p =  0.004) and 
mostly non-neutropenic (23.2 vs 32.5% of the patients, 
p =  0.038). At ICU admission, patients who underwent 
BAL had a more severe respiratory disease (higher respir-
atory rate (34 [28–40]/min vs 32 [26–38]/min p = 0.03), 
diffuse pulmonary involvement on chest X-ray (involve-
ment of more than 1 quadrant in 71.6 vs 55% of the 
patients, respectively, p  =  0.001) and were more often 
invasively mechanically ventilated in the first 24  h (58.1 
vs 35.6%, respectively, p  <  0.0001). No diagnosis could 
be performed in 26/155 (16.8%) patients who underwent 
BAL and in 52/449 (11.6%) of the remaining patients 
(p =  0.13). Hospital mortality rate was 48% for patients 
Fig. 2 Hospital mortality according to ARF etiology (univariate analy‑
sis). Undetermined ARF etiology has been used as a reference
Fig. 3 Hospital mortality according to diagnostic category. Survival 
curves were obtained using the Kaplan Meier estimator. Four 
diagnostic categories were compared: (1) Infectious: pneumonia as 
defined by a clinically or microbiologically documented low respira‑
tory tract infection. (2) Noninfectious: patients with non‑infectious 
diagnoses, mostly corresponding to cases of ARF from pulmonary 
infiltration by the malignancy [26], cardiac pulmonary edema and 
drug‑related pulmonary toxicity [27]. (3) Opportunistic infection: 
patients with ARF from opportunistic infections (probable or proven 
invasive pulmonary aspergillosis according to EORTC criteria [37], 
pneumocystis pneumonia, other cases of invasive fungal infec‑
tions, CMV infections or parasitic infections [33]. (4) Undetermined 
diagnosis
Fig. 4 Multivariable analysis of risk factors for hospital mortality. Box 
size is proportional to the accuracy of the estimate. A selection pro‑
cedure was performed using a backward algorithm with a stopping 
criteria defined by p values below 0.05 for all variables included in the 
model. Goodness‑of‑fit test of the final model was checked using the 
le Cessie–van Houwelingen test statistic
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who undergone BAL and 40% for those who did not 
(p  =  0.13). Strikingly, diagnosis was brought by BAL in 
37 (23.9%) patients of the BAL group, among whom BAL 
was the only positive diagnostic test for 28 (18%) patients 
(including 9 pneumocystis pneumonias, 9 bacterial pneu-
monias, 5 viral pneumonias, 2 invasive pulmonary asper-
gillosis, 1 intra-alveolar hemorrhage, 1 hypersensitivity 
pneumonitis and 1 pulmonary toxoplasmosis). For 92 
patients (59.4%), noninvasive tests were the unique posi-
tive investigations. Diagnosis was brought by both tech-
niques in 9 cases (5.8%). More specifically, among the 30 
patients with invasive pulmonary aspergillosis overall, 14 
diagnoses were performed in the BAL group, in whom 
2 patients were diagnosed with BAL, 11 patients were 
diagnosed with noninvasive techniques and 1 patient was 
diagnosed with both procedures. Among the 22 pneumo-
cystis pneumonia overall, 13 diagnoses were performed in 
the BAL group, in whom 9 patients were diagnosed with 
BAL as sole positive investigation, 2 patients were diag-
nosed with noninvasive microbiological investigations 
and 2 patients were diagnosed with both techniques.
Discussion
In this multicenter study conducted on a prospective 
cohort of 604 patients with ARF and HM, an undeter-
mined etiological diagnosis was strongly associated with 
higher hospital mortality. Although previously suggested, 
this is the largest study that specifically addressed this 
major clinical question. Moreover, in this study, BAL 
remained an important diagnostic tool for pneumocystis 
pneumonia but did not improve diagnostic rate or out-
come of ARF.
One of the striking results of the present work is the 
lower rate of undetermined diagnosis than previously 
reported (12.9 vs 20–30%) [7, 9, 18, 33, 35]. This result 
might be related to the recent advances in the manage-
ment of patients with HM as well as non-immunocom-
promised patients and the improvement of noninvasive 
tests [40–45] leading to higher number of diagnoses. By 
multivariate analysis adjusted on confounders, having an 
undetermined ARF etiology was independently associ-
ated with mortality.
The impact of undetermined ARF etiology on outcome 
has been assessed only in a single-center study on can-
cer patients [18]. In that study, patients in whom no ARF 
etiology could be identified had a 66% mortality rates, 
and those with known ARF etiology had a 43% mortality 
rate (p = 0.008), in the same ranges than both groups in 
the present study [18]. Furthermore, a more recent study 
from our group on patients with solid tumors and HM 
reported the same finding [32].
Besides undetermined ARF etiology, this study identi-
fies three factors significantly associated with hospital 
mortality, namely IMV in the first 24 h, invasive pulmo-
nary aspergillosis and a SOFA score >7. IMV is a well-
known risk factor for death among hematology patients 
with ARF [18, 32, 46, 47]. Invasive fungal infections such 
as pulmonary aspergillosis have also been associated with 
high-case fatality rates in this population [18, 48].
Noteworthy, diagnostic impact of bronchoscopy and 
BAL was limited in this study, in agreement with ear-
lier findings [32], even if it was performed in a sub-
group of patients. As noninvasive diagnostic tests have 
been widely used, BAL was the only yielding test in few 
patients. In a randomized controlled trial published 
in 2010, we also reported that BAL was diagnostic in 
only 18% of the patients and that a strategy without 
bronchoscopy and BAL was not inferior to routine use 
of BAL [33]. Such low diagnostic yield from BAL may 
pertain to the number of patients receiving prophy-
laxis or empirical therapy, to the number of AHSCT 
recipients in whom all diagnostic tests are less efficient 
and to the experience of this study group used to man-
age hematology patients using noninvasive diagnos-
tic tests. However, it should be noted that BAL had 
high diagnostic yield in pneumocystis pneumonia and 
remains the only reliable diagnostic tool in patients 
with alveolar hemorrhage, hypersensitivity pneumoni-
tis, drug-related pulmonary toxicity or acute interstitial 
pneumonia. Diagnostic contribution of alveolar cellular 
patterns and cytology still needs additional investiga-
tions [49].
This study has several limitations. First, as in a cohort 
study with no protocolized intervention, not all diag-
nostic tests could be performed in each patient. Iden-
tifying ARF etiology may be related to the number of 
tests performed. Moreover, patients who died in the 
first days of ICU admission would not have number of 
investigation tests. Yet, in this study, patients with unde-
termined diagnosis died earlier than the others (Fig. 3). 
Then, undetermined diagnosis might be actually some 
of undiagnosed infections. Moreover, although all the 
participating ICUs were high-volume centers used to 
manage critically ill hematological patients, we could 
not be sure that diagnosis strategy was the same in all 
centers. However, rate of undetermined diagnosis was 
lower than the rate in previous study [33], and we did 
not find any center effect. Second, BAL was performed 
according to physician’s decision, and most of patients 
were intubated before BAL. However, diagnostic yield 
of bronchoscopy and BAL is in the same ranges than 
previous reports. Third, these results were obtained in 
high-volume centers and may not be generalizable to all 
centers. However, most of hematology patients are man-
aged in highly specialized comprehensive cancer cent-
ers with unique collaboration between hematologists, 
Page 8 of 9Contejean et al. Ann. Intensive Care  (2016) 6:102 
intensivists and other specialists. Fourth, this cohort 
included a wide variability of patients, in terms of HM, 
neutropenia, stage of disease, cause of ARF and stem 
cell transplantation. Last, none of the patients with-
out documented ARF etiology underwent pulmonary 
biopsy. However, active malignancies and thrombo-
cytopenia, severe hypoxemic pulmonary involvement, 
associated organ dysfunction and hemostatic disor-
ders precluded this invasive investigation. Neverthe-
less, mortality related to undetermined diagnosis in this 
study suggests to reappraise the risk–benefit ratio for 
these high-risk patients.
Conclusions
Despite comprehensive diagnostic workout, failure to 
document ARF etiology occurs in 13% of critically ill 
hematology patients and is associated with increased 
mortality. Studies are needed to guide second-line diag-
nostic strategy and the place of pulmonary biopsy in 
hematology patients with ARF.
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